CAS 1812-30-2|bromazepam|Novo-bromazepam|Bromazepamum [inn-latin]|Nu-Bromazepam|Ultramidol|Lexotan|Lexaurin|Apo-Bromazepam|Creosedin|Somalium|7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one|Lex...

General Information

Structure

Molecular Formula

C₁₄H₁₀BrN₃O

Molecular Mass

316.1527

Exact Mass

315.00072396

Charge

InChI

InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)

InChIKey

VMIYHDSEFNYJSL-UHFFFAOYSA-N

Canonic Smiles

O=C1CN=C(c2c(N1)ccc(c2)Br)c1ccccn1

Isomeric Smiles

Brc1cc2c(NC(=O)CN=C2c2ncccc2)cc1

Calculated Properties

JChem

Acid pKa

12.238634

H Acceptors

H Donor

LogD (pH = 5.5)

2.5442781

LogD (pH = 7.4)

2.5448925

Log P

2.5449064

Molar Refractivity

76.9851

Polarizability

28.506214

Polar Surface Area

54.35

Rotatable Bonds

Lipinski's Rule of Five

true

ALOGPS 2.1

Log P

2.09

LOG S

-3.9

Solubility (Water)

3.99e-02 g/l

Data Source

Academic Data

Commercial Catalog

Data Source

Names and Identifiers

Brand Name

DurazanilNovo-bromazepamLexaurinLexotanApo-BromazepamCreosedinNu-BromazepamUltramidolLexotanilLexomilLexiliumSomaliumLekotamCalmepamGen-BromazepamNormocCompediumLectopamCompendiumLexotan, Lexotanil

Synonyms

7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-oneBromazepamum [inn-latin]Bromazepam7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one7-溴-5-(2-吡啶基)-3H-1,4-苯并二氮杂卓-2(1H)-酮溴西泮BromazepamCompendiumLexotanLexotanilDurazanilLexiliumLexomilNormocCreosedin7-Bromo-1,3-dihydro-5-(2-pyridinyl)-2H-1,4-benzodiazepin-2-oneRo 5-3350NSC 140669

IUPAC Traditional name

bromazepam

IUPAC name

7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

Names and Identifiers

Registration numbers

CAS Number

KEGG ID

Wikipedia Title

CHEMBL

Unique Ingredient Identifier

ATC CODE

PubChem CID

Chemspider ID

EC Number

DrugBank ID

MDL Number

PubChem SID

4650569424891754160964802

Registration numbers

Properties

Physical Property

Hydrophobicity(logP)

2.05 [SANGSTER (1994)]

Flash Point

51.8 °F

11 °C

Apperance

Crystalline Solid

Melting Point

205-210°C (dec.)

Product Information

Grade

analytical standard, for drug analysis

drug standard

Concentration

1.0 mg/mL±5% in methanol

Purity

≥98%

Certificate of Analysis

Download link

Properties

Related Proteins

No Data Available

Click here to submit data

Molecular Spectra

No Data Available

Click here to submit data

Molecule Details

DrugBank

DB01558

Drug Groups

illicit; approved

Description

One of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances.

Indication

For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.

Pharmacology

Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam shares with other benzodiazepines the risk of abuse, misuse, psychological and/or physical dependence. According to many psychiatric experts Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.

Affected Organisms

Humans and other mammals

Biotransformation

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes).

Absorption

Bioavailability is 84% following oral administration.

Half Life

10-20 hours

References

• Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [Pubmed]

• Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. [Pubmed]

• van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. [Pubmed]

• Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI: Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70. [Pubmed]

External Links

• [Wikipedia]

Wikipedia

Bromazepam

Sigma Aldrich

B4144

Biochem/physiol Actions
抗焦虑药

TRC

B678500

Controlled substance (depressant). Anxiolytic.

Molecule Details

References

PubChem Literature

From Data Sources

• Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. Pubmed

• van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. Pubmed

• Chalmers, P., et al.: Anesthesia, 39, 370 (1973)

• Schwartz, M.A., et al.: J. Pharm. Sci., 62, 1776 (1973)

• Hassan, M.M., et al.: Anal. Profiles Drug Subs., 16, 1 (1973)

References

Bioactivity

PubChem BioAssay

Bioactivity

Data Source

Academic Data

Commercial Catalog

Names and Identifiers

Brand Name

DurazanilNovo-bromazepamLexaurinLexotanApo-BromazepamCreosedinNu-BromazepamUltramidolLexotanilLexomilLexiliumSomaliumLekotamCalmepamGen-BromazepamNormocCompediumLectopamCompendiumLexotan, Lexotanil

Synonyms

IUPAC Traditional name

bromazepam

IUPAC name

7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

Registration numbers

CAS Number

KEGG ID

Wikipedia Title

CHEMBL

Unique Ingredient Identifier

ATC CODE

PubChem CID

Chemspider ID

EC Number

DrugBank ID

MDL Number

PubChem SID

4650569424891754160964802

Molecule Details

DrugBank

DB01558

Drug Groups

illicit; approved

Description

One of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances.

Indication

For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.

Pharmacology

Affected Organisms

Humans and other mammals

Biotransformation

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes).

Absorption

Bioavailability is 84% following oral administration.

Half Life

10-20 hours

References

• Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [Pubmed]

• van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. [Pubmed]

External Links

• [Wikipedia]

Wikipedia

Bromazepam

Sigma Aldrich

B4144

Biochem/physiol Actions
抗焦虑药

TRC

B678500

Controlled substance (depressant). Anxiolytic.

References

PubChem Literature

From Data Sources

• Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. Pubmed

• van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. Pubmed

• Chalmers, P., et al.: Anesthesia, 39, 370 (1973)

• Schwartz, M.A., et al.: J. Pharm. Sci., 62, 1776 (1973)

• Hassan, M.M., et al.: Anal. Profiles Drug Subs., 16, 1 (1973)

Bioactivity

PubChem BioAssay

Properties

Physical Property

Hydrophobicity(logP)

2.05 [SANGSTER (1994)]

Flash Point

51.8 °F

11 °C

Apperance

Crystalline Solid

Melting Point

205-210°C (dec.)

Product Information

Grade

analytical standard, for drug analysis

drug standard

Concentration

1.0 mg/mL±5% in methanol

Purity

≥98%

Certificate of Analysis

Download link

Molecule

ID:1342